Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucles(t)ide Analogue Therapy
Rong Fan, Bin Zhou, Min Xu, et al.
Clinical Gastroenterology and Hepatology (2019) Vol. 18, Iss. 3, pp. 719-727.e7
Open Access | Times Cited: 87

Showing 1-25 of 87 citing articles:

A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook
Anna Kramvis, Kyong–Mi Chang, Maura Dandri, et al.
Nature Reviews Gastroenterology & Hepatology (2022) Vol. 19, Iss. 11, pp. 727-745
Open Access | Times Cited: 114
Guidelines for the Prevention and Treatment of Chronic Hepatitis B (version 2022)
Hong You, Fu‐Sheng Wang, Taisheng Li, et al.
Journal of Clinical and Translational Hepatology (2023) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 95
Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation
Wai‐Kay Seto, K. S. H. Liu, Lung‐Yi Mak, et al.
Gut (2020) Vol. 70, Iss. 4, pp. 775-783
Closed Access | Times Cited: 80
Guidelines for Prevention and Treatment of Chronic Hepatitis B
Guiqiang Wang, Zhongping Duan
Journal of Clinical and Translational Hepatology (2021) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 76
Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature‐Mutation in Treated Chronic Hepatitis B Patients
Qi Huang, Bin Zhou, Dawei Cai, et al.
Hepatology (2020) Vol. 73, Iss. 1, pp. 41-52
Open Access | Times Cited: 74
APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients
Jia‐Horng Kao, Wen‐Juei Jeng, Qin Ning, et al.
Hepatology International (2021) Vol. 15, Iss. 4, pp. 833-851
Closed Access | Times Cited: 73
The times they are a-changing – A refined proposal for finite HBV nucleos(t)ide analogue therapy
Thomas Berg, Pietro Lampertico
Journal of Hepatology (2021) Vol. 75, Iss. 2, pp. 474-480
Closed Access | Times Cited: 57
Incidence of Hepatic Decompensation After Nucleos(t)ide Analog Withdrawal: Results From a Large, International, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study)
Grishma Hirode, Bettina E. Hansen, Chien‐Hung Chen, et al.
The American Journal of Gastroenterology (2023) Vol. 118, Iss. 9, pp. 1601-1608
Open Access | Times Cited: 25
Combining Hepatitis B Virus RNA and Hepatitis B Core–Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen–Positive Patients With Chronic Hepatitis B
Rong Fan, Jie Peng, Qing Xie, et al.
The Journal of Infectious Diseases (2020) Vol. 222, Iss. 4, pp. 611-618
Open Access | Times Cited: 70
HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy
Lung‐Yi Mak, Gavin Cloherty, Danny Ka‐Ho Wong, et al.
Hepatology (2020) Vol. 73, Iss. 6, pp. 2167-2179
Closed Access | Times Cited: 69
Circulating HBV RNA: From biology to clinical applications
Rui Deng, Shi Liu, Sheng Shen, et al.
Hepatology (2022) Vol. 76, Iss. 5, pp. 1520-1530
Closed Access | Times Cited: 32
Quantification of circulating HBV RNA expressed from intrahepatic cccDNA in untreated and NUC treated patients with chronic hepatitis B
Barbara Testoni, Caroline Scholtès, Marie‐Laure Plissonnier, et al.
Gut (2023) Vol. 73, Iss. 4, pp. 659-667
Open Access | Times Cited: 22
Hepatitis B surface antigen, core‐related antigen and HBV RNA: Predicting clinical relapse after NA therapy discontinuation
Apichat Kaewdech, Pisit Tangkijvanich, Pimsiri Sripongpun, et al.
Liver International (2020) Vol. 40, Iss. 12, pp. 2961-2971
Closed Access | Times Cited: 40
Performance of the cobas® HBV RNA automated investigational assay for the detection and quantification of circulating HBV RNA in chronic HBV patients
Caroline Scholtès, Aaron T. Hamilton, Marie‐Laure Plissonnier, et al.
Journal of Clinical Virology (2022) Vol. 150-151, pp. 105150-105150
Open Access | Times Cited: 25
High accuracy model for HBsAg loss based on longitudinal trajectories of serum qHBsAg throughout long-term antiviral therapy
Rong Fan, Siru Zhao, Junqi Niu, et al.
Gut (2024) Vol. 73, Iss. 10, pp. 1725-1736
Closed Access | Times Cited: 5
Recent Advances in Understanding, Diagnosing, and Treating Hepatitis B Virus Infection
Magda Rybicka, Krzysztof Piotr Bielawski
Microorganisms (2020) Vol. 8, Iss. 9, pp. 1416-1416
Open Access | Times Cited: 33
Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg‐Negative Chronic Hepatitis B
Florian van Bömmel, Thomas Berg
Hepatology Communications (2021) Vol. 5, Iss. 10, pp. 1632-1648
Open Access | Times Cited: 28
Utility of novel viral and immune markers in predicting HBV treatment endpoints: A systematic review of treatment discontinuation studies
Georgia Zeng, Apostolos Koffas, Lung‐Yi Mak, et al.
JHEP Reports (2023) Vol. 5, Iss. 6, pp. 100720-100720
Open Access | Times Cited: 12
Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants
Alexander Thompson, Kathy Merlock Jackson, Sara Bonanzinga, et al.
Hepatology Communications (2023) Vol. 7, Iss. 8
Open Access | Times Cited: 11
Detection technology and clinical applications of serum viral products of hepatitis B virus infection
Ying Liu, Di Wu, Kui Zhang, et al.
Frontiers in Cellular and Infection Microbiology (2024) Vol. 14
Open Access | Times Cited: 4
A study on pregenomic RNA and factors in the pregnant and postpartum women with chronic HBV infection based on real world
Juan Tang, Qiongfang Wu, Ziyue Zhang, et al.
Frontiers in Cellular and Infection Microbiology (2025) Vol. 15
Open Access
HBeAg-positive patients with HBsAg < 100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation
Yandi Xie, Minghui Li, Xiaojuan Ou, et al.
Journal of Gastroenterology (2021) Vol. 56, Iss. 9, pp. 856-867
Open Access | Times Cited: 25
Association of Serum Hepatitis B Virus RNA With Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Under Nucleos(t)ide Analogues Therapy
Shi Liu, Rui Deng, Bin Zhou, et al.
The Journal of Infectious Diseases (2021) Vol. 226, Iss. 5, pp. 881-890
Closed Access | Times Cited: 24
Sera of Individuals Chronically Infected with Hepatitis B Virus (HBV) Contain Diverse RNA Types Produced by HBV Replication or Derived from Integrated HBV DNA
Igor Zaiets, Sumedha Gunewardena, Stephan Menne, et al.
Journal of Virology (2023) Vol. 97, Iss. 3
Open Access | Times Cited: 10
EASL Clinical Practice Guidelines on the management of hepatitis B virus infection
Markus Cornberg, Lisa Sandmann, Jerzy Jaroszewicz, et al.
Journal of Hepatology (2025)
Closed Access
Page 1 - Next Page

Scroll to top